Revelation Biosciences, Inc. (REVB)
| Market Cap | 3.24M-85.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a-27.0% |
| EPS | n/a+74.5% |
| Shares Out | 3.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,312 |
| Open | 0.76 |
| Previous Close | 0.75 |
| Day's Range | 0.76 - 0.84 |
| 52-Week Range | 0.75 - 6.24 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
$REVB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in REVB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by REVB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
REVB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New REVB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to REVB from public contracts
Source: USAspending.gov
REVB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from REVB’s recent data — informational, not investment advice